Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00337168 · ClinicalTrials.gov registry record · Phase 2
S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00337168 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 36 participants.
The verdict
NCT00337168, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cytarabine and clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving cytarabine together with clofarabine works in treating patients with relapsed or refractory acute lymphoblastic leukemia.
Interventions
- DRUG clofarabine
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2006-10 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00337168
The ClinicalTrials.gov registry entry for NCT00337168 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which clofarabine is the first listed.
NCT00337168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00337168 about?
NCT00337168 is a clinical study titled "S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia". RATIONALE: Drugs used in chemotherapy, such as cytarabine and clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase I...
What is the current status of trial NCT00337168?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2006-10. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00337168?
The interventions under investigation include: clofarabine (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00337168?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.